img/produkte/durchfluss/accutase.jpgPhoenix Flow Systems is now the parent company of Innovative Cell Technologies, Inc. (ICT). ICT is the world leader in developing and manufacturing, as well as being the sole source for non-mammalian enzyme complexes that will replace trypsin. The company has already introduced two unique products and more will follow. By  developing enzyme solutions that contain no mammalian or bacterialderived products, ICT has overcome many of the problems associated with using products like trypsin, which are derived from such sources. In addition to  eliminating a variety of shortcomings associated with the use of trypsin, ICT’s enzyme products also outperform  trypsin for cell detachment and cell/tissue dissociation. In addition, they are less damaging to cells, preserving other cellular constituents that are often damaged or destroyed by trypsin treatment.


Accutase is a novel enzyme complex that exhibits protease (including collagenase) activity. This maximizes its versatility for cell detachment and tissue dissociation applications. Accutase has been developed to meet the most demanding needs for gentle and effective detachment of adherent cells and has the following characteristics:


Accutase does not contain any mammalian or bacterial-derived products. This ensures that it does not have any of the common problems associated with products that are derived from those sources. This further underscores the advantages of using Accutase over conventional protease products. Accutase has been extensively tested in research and biopharmaceutical laboratories and has been shown effective on a wide variety of cells. A brief list (not intended to be comprehensive) of the cell lines that have been tested include the following:
fibroblasts, keratinocytes, vascular endothelial cells, hepatocytes, vascular smooth muscle cells, hepatocyte progenitors, primary chick embryo neuronal cells, bone marrow stem cells, adherent CHO and BHK cells, macrophages, 293 cells, L929 cells, immortalized mouse testicular germ cells, 3T3, Vero, COS, HeLa, NT2, MG63,  M24 and A375 metastatic melanoma, gliomas U251 and D54, HT 1080 fibrosarcoma cells and Sf9 insect cells. Each lot of Accutase is individually formulated to rigid quality control standards, it’s enzymatic activitiy is measured with synthetic chromagenic tetrapeptides and tested for its capability of effective cell detachment. Accutase is supplied in Dulbecco’s PBS containing 0.5mM EDTA.4Na and phenol red, in 100ml bottles.



de German